Clinical Trials Search
A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Age 50 or Older with Intermediate-2 and High Risk Myelodysplastic Syndrome
The purpose of this study is to find out if a reduced-intensity transplant works better than the standard treatment for Myelodysplastic Syndrome (MDS).
Compare the three-year overall survival probabilities between the two study arms using an intent-to-treat analysis. Arm 1: RIC alloHCT Arm 2: Hypomethylating Therapy / Best Supportive Care 1. Compare leukemia-free survival (LFS) at 3 years from enrollment 2. Compare QOL measures between treatment arms